Skip to content

Jon Berner

3 papers in the library · 8 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

Non-randomized rapamycin augmentation of chronic self-administered ketamine provides subjective improvement in diverse phenotypes

Frontiers in Psychiatry August 26, 2026 Jon Berner

Background Multiple preclinical and clinical reports suggest that rapamycin augmentation may increase the safety and efficacy of ketamine treatment. Population variability in patient biochemical gain-of-function and phenotypic admixtures, however, has slowed initial investigations into patient selection and dose finding. Methods A single-center, retrospective chart review identified 101...

mTORC1 activation in presumed classical monocytes: observed correlation with human size variation and neuropsychiatric disease.

Aging July 26, 2024 Karl Berner, Naci Oz, Alaattin Kaya et al. 1 citation

Gain of function disturbances in nutrient sensing are likely the largest component in human age-related disease. Mammalian target of rapamycin complex 1 (mTORC1) activity affects health span and longevity. The drugs ketamine and rapamycin are effective against chronic pain and depression, and both affect mTORC1 activity. Our objective was to measure phosphorylated p70S6K, a marker for mTORC1...

Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study.

Discover Mental Health April 17, 2024 Jon Berner, Animesh Acharjee 7 citations

Depression is a disorder with variable presentation. Selecting treatments and dose-finding is, therefore, challenging and time-consuming. In addition, novel antidepressants such as ketamine have sparse optimization evidence. Insights obtained from metabolomics may improve the management of patients. The objective of this study was to determine whether compounds in the cerebrospinal fluid (CSF)...